CICC, acting as Sole Lead Underwriter and Bond Trustee, successfully assisted Shanghai Junshi Biosciences Co., Ltd. (“Junshi Bio” or the “Company”) in Non-public Offering of Convertible Bonds of Innovation and Entrepreneurship Nature (the “Offering”) on Feb 23, 2018. The offering size was RMB 200 MM, with tenor of 6 years, coupon rate of 10.35% per year and convertible premium rate of 9.31%. The offering is of convertible bonds of innovation and entrepreneurship nature under the CSRC’s latest guiding opinions announced in July 2017, the largest private placement of convertible bonds by size up to date and the first private placement of convertible bonds by an innovator drug enterprise which positively responded to financial support for enterprises of Innovation and Entrepreneurship Nature and made significant market influence.

Junshi Bio (Stock Code: 833330) was established in 2012 as an innovative biopharma company focusing on R&D and industrialization of innovative monoclonal antibody drugs and other protein drugs for treatment purposes. The Company has built China’s top-class technology platform for R&D of humanized antibody drugs and developed a rich product line. The Company’s core product in R&D phase, JS001, is the first anti-PD-1 monoclonal antibody drug among domestic players applied to and approved by CFDA for clinical trials, and was approved by FDA for clinical trials in Jan 9, 2018. As of Feb. 24, 2018, Junshi Bio recorded total market cap. of RMB13.3 Bn, having the highest valuation among innovator drug companies listed on the NEEQ.

Acting as the sponsoring broker of Junshi Bio, CICC has been providing full-spectrum capital market services, such as private placement (equity), bond issuance and market making. In the Offering, with a deep understanding of the innovative drug industry and customer’s preference, CICC led execution, assisted in communication with regulators and ensured smooth regulatory review and issuance on tight timetable. As a leading investment bank with “China Roots, International Reach”, CICC will continue to utilize its capital market expertise as well as its full-spectrum capital market services to provide continuous support to our customers in terms of capital market operation and business development.